Combined Matrix Concept in Delivery of Bioactive Polypeptides

  • Paul Y. Wang
  • Evelyn Kothe
Part of the Polymer Science and Technology book series (PST, volume 38)


Generally, a polymer implant may release a drug by diffusion at the same time with dissolution of the polymer component without depolymerization (Type A) or by erosion involving depolymerization (Type B). The Type A material induces immune response while the Type B polymer may lead to toxicity problems. It is proposed that a combination of the two types of polymer may attenuate the intensity of the biological responses, because the presence of one in an implant of the same weight reduces the amount of the other. However, it is important to know if sustained delivery may be achieved by such an implant. In this study, partially hydrolyzed poly(vinyl acetate) (PVA) and polycaprolactone (PCL) were chosen as the model Type A. and B polymers, respectively, to evaluate this objective first in vitro with methylene blue (MB) as a model drug. Results show that sustained delivery can be effected, but PCL erosion did not occur as intended. Therefore, PCL served only as a passive component of the implant. while PVA was eroded with the release of MB. Consequently, it was inferred that a polymer may not be required as a passive component. Tests with insulin in a compressed solid admixture with palmitic acid showed that reduction of hyperglycemia in diabetic Wistar rat could be effected repro-ducibly for at least 5 weeks. Thus, the present study, originally planned to test a proposed concept, indicates that non-polymeric materials of known biocompatibility may be suitable for delivery of many bioactive polypeptides as well.


Methylene Blue Palmitic Acid Maleic Anhydride Vinyl Acetate Vinyl Alcohol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. Y. Wang. “Proc. 11th Internat. Symp. Controlled Release Bioact. Materials”, Controlled Release Soc., Lincolnshire, IL, 1984, p. 121.Google Scholar
  2. 2.
    P. Y. Wang, & C. Chambers in: “Polymeric Materials and Artificial Organs”, C. G. Gebelein, Ed., ACS Symp. Ser. 256, Washington, DC, 1984, p. 31.CrossRefGoogle Scholar
  3. 3.
    H. W. Coover, Jr. & J. M. McIntire in: “Tissue Adhesives in Surgery”, T. Matsumoto, Ed., Med. Exam. Publishing, Flushing, NY, 1972, p. 154.Google Scholar
  4. 4.
    A. Schiffrin, M. Desrosiers & M. Belmonte, Diabetes Care. 6, 166 (1983).CrossRefGoogle Scholar
  5. 5.
    E. B. Marliss, D. Caron, A. M. Albisser & B. Zinman, Diabetes Care, 4, 325 (1981).Google Scholar
  6. 6.
    H. Buchwald. J. Barbosa & R. L. Varco, Lancet, 2, 1233 (1981).CrossRefGoogle Scholar
  7. 7.
    H. B. Croxatto, S. Diaz, P. Miranda, K. Elamsson & E. D. B. Johansson. Contraception, 23, 197 (1981).CrossRefGoogle Scholar
  8. 8.
    C. G. Pitt, T. A. Mark & A. Schindler in: “Controlled Release of Bioactive Materials”, R. Baker, Ed., Academic Press, 1980, p. 19.CrossRefGoogle Scholar
  9. 9.
    J. Heller in: “Recent Advances in Drug Delivery Systems”, J. M. Anderson & S. W. Kim. Eds., Plenum Press, NY, 1984, p. 101.CrossRefGoogle Scholar
  10. 10.
    H. M. Creque, R. Langer & J. Folkman, Diabetes, 29, 37 (1980).CrossRefGoogle Scholar
  11. 11.
    E. R. Edelman, J. Kost, H. Bobeck & R. Langer. J. Biomed. Mater. Res., 19, 67 (1985).CrossRefGoogle Scholar
  12. 12.
    J. Kost, K. Leong & J. Langer. “Proc. 12th Internat. Symp. Controlled Release Bioact. Materials”, 1985, p. 73.Google Scholar
  13. 13.
    P. Y. Wang, Diabetes, 36, 1068 (1987).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Paul Y. Wang
    • 1
  • Evelyn Kothe
    • 1
  1. 1.Laboratory of Chemical Biology, Institute of Biomedical EngineeringUniversity of TorontoTorontoCanada

Personalised recommendations